ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO834

FRA-2 (Fosl2) Epigenomic and Splicing Dynamics in Crescentic Glomerulopathies

Session Information

Category: Glomerular Diseases

  • 1401 Glomerular Diseases: Mechanisms, including Podocyte Biology

Authors

  • Bronstein, Robert, Stony Brook University, Stony Brook, New York, United States
  • Gujarati, Nehaben A., Stony Brook University, Stony Brook, New York, United States
  • Salant, David J., Boston University, Boston, Massachusetts, United States
  • Mallipattu, Sandeep K., Stony Brook University, Stony Brook, New York, United States
Background

Proliferative glomerulopathies are end-stage kidney diseases. Their complex etiology is apparent in disorders like diabetes, sickle cell disease and HIV. There are no curative therapies, therefore a more mechanistic view of disease features is needed. A patho-proliferative cell in the kidney glomerulus is the parietal epithelial cell (PEC) lining the inner wall of Bowman’s capsule, and growing evidence shows it contributes to disease progression - forming crescentic lesions in diseases such as focal segmental glomerulosclerosis. Our two mouse models of proliferative glomerulopathy (nephrotoxic serum nephritis and podocyte-specific Klf4 knock-down) identify transcription FRA-2 as crucial to disease progression.

Methods

10X Multiomic datasets were generated from nephrotoxic serum (NTS – Days 0,7 & 14) and podocyte-specific Klf4 deletion models of proliferative glomerulopathy. Seurat (RNA) and ArchR (ATAC) were the primary R tools used in bioinformatic analysis, with: CellChat, Monocle3 & clusterProfiler. FRA-2 immunoprecipitation and mass spectrometry (RIME) was performed in a PEC cell line, as were Fosl2 knock-down experiments.

Results

Analysis of multiomic features after glomerular injury identified Fosl2 and its motif as enriched in PECs (Fig. 1A). Ligand-receptor interactions in NTS dataset pointed to PEC-specific Spp1/Cd44 interactions as conserved molecular features in these disease models (Fig. 1B). RIME analysis of Fosl2 interactors showed enrichment in splicing factors, in agreement with Fosl2+/Cd44+ sub-clusters 1&2 (Fig. 1C). Knock-down of Fosl2 in an immortalized PEC cell line resulted in a reduction in Cd44 isoforms V7-V9 (Fig. 1D). Gene-Splice Junction (SJ) relationships in the temporal and pseudo-time transition between PECs and Myofibroblasts point to isoform switching of key fibrosis genes (Fig. 1E).

Conclusion

These data suggest that FRA-2 (Fosl2) is a regulatory TF in proliferative glomerulopathies across the crescentic to fibrotic boundary (Day 7 to 14) - through the modification of alternative splicing dynamics.

Fig. 1

Funding

  • NIDDK Support